Drug major Dr Reddy's Laboratories on Wednesday said it has launched cancer treatment drug Capecitabine tablets in the US market.
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA).
Quoting IQVIA Health data, Dr Reddy's said the Xeloda brand and generic had US sales of approximately USD 90 million for the most recent 12 months ending in October 2020.
Dr Reddy's Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.
Shares of Dr Reddy's Laboratories were trading 0.98 per cent lower at Rs 4,650 apiece on BSE.
Just one email a week